Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2025-07-23 6-K US FDA REVIEW EXTENDED FOR BLENREP View Document
2025-07-23 6-K TRANSACTION IN OWN SHARES View Document
2025-07-22 6-K TRANSACTION IN OWN SHARES View Document
2025-07-21 6-K TRANSACTION IN OWN SHARES View Document
2025-07-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-07-18 6-K BLENREP US ODAC OUTCOME View Document
2025-07-18 6-K TRANSACTION IN OWN SHARES View Document
2025-07-17 6-K GSKS SHINGRIX FULLY LIQUID FDA APPROVAL View Document
2025-07-17 6-K TRANSACTION IN OWN SHARES View Document
2025-07-16 6-K TRANSACTION IN OWN SHARES View Document
2025-07-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-07-15 6-K TRANSACTION IN OWN SHARES View Document
2025-07-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-07-14 6-K GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA View Document
2025-07-14 6-K TRANSACTION IN OWN SHARES View Document
2025-07-11 6-K TRANSACTION IN OWN SHARES View Document
2025-07-10 6-K TRANSACTION IN OWN SHARES View Document
2025-07-09 6-K TRANSACTION IN OWN SHARES View Document
2025-07-08 6-K TRANSACTION IN OWN SHARES View Document
2025-07-07 6-K GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD View Document
2025-07-07 6-K TRANSACTION IN OWN SHARES View Document
2025-07-07 6-K TRANSACTION IN OWN SHARES View Document
2025-07-03 6-K TRANSACTION IN OWN SHARES View Document
2025-07-02 6-K TRANSACTION IN OWN SHARES View Document
2025-07-01 6-K TOTAL VOTING RIGHTS View Document
2025-07-01 6-K TRANSACTION IN OWN SHARES View Document
2025-06-30 6-K TRANSACTION IN OWN SHARES View Document
2025-06-27 6-K TRANSACTION IN OWN SHARES View Document
2025-06-26 6-K TRANSACTION IN OWN SHARES View Document
2025-06-25 6-K TRANSACTION IN OWN SHARES View Document
2025-06-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-24 6-K DIRECTOR DECLARATION View Document
2025-06-24 6-K TRANSACTION IN OWN SHARES View Document
2025-06-23 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-23 6-K LINERIXIBAT FILE ACCEPTED BY EMA View Document
2025-06-23 6-K TRANSACTION IN OWN SHARES View Document
2025-06-20 6-K AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK View Document
2025-06-20 6-K TRANSACTION IN OWN SHARES View Document
2025-06-20 6-K TRANSACTION IN OWN SHARES View Document
2025-06-18 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE View Document
2025-06-18 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS View Document
2025-06-18 6-K TRANSACTION IN OWN SHARES View Document
2025-06-17 6-K TRANSACTION IN OWN SHARES View Document
2025-06-16 6-K TRANSACTION IN OWN SHARES View Document
2025-06-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-13 6-K TRANSACTION IN OWN SHARES View Document
2025-06-13 6-K GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA View Document
2025-06-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-12 6-K TRANSACTION IN OWN SHARES View Document
2025-06-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-11 6-K TRANSACTION IN OWN SHARES View Document
2025-06-10 6-K TRANSACTION IN OWN SHARES View Document
2025-06-09 6-K TRANSACTION IN OWN SHARES View Document
2025-06-06 6-K TRANSACTION IN OWN SHARES View Document
2025-06-05 6-K TRANSACTION IN OWN SHARES View Document
2025-06-04 6-K GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME View Document
2025-06-04 6-K TRANSACTION IN OWN SHARES View Document
2025-06-03 6-K TRANSACTION IN OWN SHARES View Document
2025-06-02 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-06-02 6-K TOTAL VOTING RIGHTS View Document
2025-06-02 6-K LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA View Document
2025-06-02 6-K TRANSACTION IN OWN SHARES View Document
2025-05-30 SD SPECIALIZED DISCLOSURE REPORT View Document
2025-05-30 6-K TRANSACTION IN OWN SHARES View Document
2025-05-29 6-K TRANSACTION IN OWN SHARES View Document
2025-05-28 6-K GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY View Document
2025-05-28 6-K TRANSACTION IN OWN SHARES View Document
2025-05-27 6-K TRANSACTION IN OWN SHARES View Document
2025-05-23 6-K POSITIVE CHMP OPINION ON BLENREP IN EU View Document
2025-05-23 6-K FDA APPROVES NUCALA COPD INDICATION View Document
2025-05-23 6-K TRANSACTION IN OWN SHARES View Document
2025-05-22 6-K TRANSACTION IN OWN SHARES View Document
2025-05-21 6-K TRANSACTION IN OWN SHARES View Document
2025-05-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-05-20 6-K TRANSACTION IN OWN SHARES View Document
2025-05-19 6-K BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN View Document
2025-05-19 6-K TRANSACTION IN OWN SHARES View Document
2025-05-16 6-K TRANSACTION IN OWN SHARES View Document
2025-05-15 25-NSE View Document
2025-05-15 6-K TRANSACTION IN OWN SHARES View Document
2025-05-14 6-K GSK TO ACQUIRE EFIMOSFERMIN View Document
2025-05-14 6-K TRANSACTION IN OWN SHARES View Document
2025-05-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-05-13 6-K UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME View Document
2025-05-13 6-K TRANSACTION IN OWN SHARES View Document
2025-05-12 6-K BLOCK LISTING INTERIM REVIEW View Document
2025-05-12 6-K TRANSACTION IN OWN SHARES View Document
2025-05-09 6-K TRANSACTION IN OWN SHARES View Document
2025-05-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-05-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-05-08 6-K LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL View Document
2025-05-08 6-K TRANSACTION IN OWN SHARES View Document
2025-05-07 6-K RESULT OF AGM View Document
2025-05-07 6-K TRANSACTION IN OWN SHARES View Document
2025-05-06 6-K TRANSACTION IN OWN SHARES View Document
2025-05-02 6-K TRANSACTION IN OWN SHARES View Document
2025-05-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-05-01 6-K TOTAL VOTING RIGHTS View Document
2025-05-01 6-K NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM View Document
2025-05-01 6-K TRANSACTION IN OWN SHARES View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299